Ampullary Adenocarcinoma: Clinical Trials

7 trials for Ampullary Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting, 1 completed, 1 unknown. 2 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Recruiting 2
Not applicable1Completed 1
Phase 11Recruiting 1
Phase 31Recruiting 1

Follow Ampullary Adenocarcinoma: new trials by email Literature Review of Ampullary Adenocarcinoma trials Research Report on Ampullary Adenocarcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR) - Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma
RecruitingAdventHealth102026-11-012026-09-29
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test - Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Phase 2RecruitingYale University542026-06-022026-09-08
PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma
mFOLFORINOX, Capecitabine or gemcitabine, Quality of life questionnaires: QLQ-C30 and PAN26 - Ampullary Adenocarcinoma
Phase 3RecruitingCentre Hospitalier Universitaire Dijon2942025-07-022025-07-11
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.
Folfirinox, Capox - Ampullary Adenocarcinoma
RecruitingFondazione Poliambulanza Istituto Ospedaliero4002023-07-012023-10-05
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
total pancreatectomy, intraportal islet autotransplantation - Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum
Phase 1 / Phase 2RecruitingUniversity Hospital, Lille362022-02-202025-09-25
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy - Pancreatic Adenocarcinoma, Pancreatic Cysts
Not applicableCompletedRuijin Hospital2682020-09-282025-12-18
Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma
treatment for ampullary adenocarcinoma - Ampullary Adenocarcinoma
UnknownFederation Francophone de Cancerologie Digestive4022017-07-072022-03-24

Narrower conditions

Cholangiocarcinoma (2)  ·  Pancreatic Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma Of Esophagus (1)  ·  Duodenal Neoplasms (1)  ·  Pancreatic Cyst (1)  ·  Pancreatitis, Chronic (1)  ·  Recurrence (1)

Broader conditions

Neoplasms (4)  ·  Carcinoma (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Adenocarcinoma (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Endocrine Gland Neoplasms (2)  ·  Endocrine System Diseases (2)  ·  Neoplasms by Site (2)  ·  Pancreatic Diseases (2)  ·  Chronic Disease (1)  ·  Cysts (1)  ·  Disease Attributes (1)  ·  Duodenal Diseases (1)

Interventions

Capecitabine (2)  ·  Floxuridine (1)  ·  Fluorouracil (1)  ·  Gemcitabine (1)  ·  Irinotecan (1)  ·  Leucovorin (1)  ·  Oxaliplatin (1)  ·  Therapeutics (1)  ·  folfirinox (1)

Sponsors

AdventHealth (1)  ·  Centre Hospitalier Universitaire Dijon (1)  ·  Federation Francophone de Cancerologie Digestive (1)  ·  Fondazione Poliambulanza Istituto Ospedaliero (1)  ·  Ruijin Hospital (1)  ·  University Hospital, Lille (1)  ·  Yale University (1)

Countries

France (3)  ·  United States (2)  ·  China (1)  ·  Italy (1)

Top investigators

Baiyong Shen, PhD (1)  ·  Kiran Turaga, MD (1)  ·  Moh'd Abu Hilal, MD, PhD (1)

Results publications

PMID 34961558, PMID 41622055, PMID 41812337, PMID 42386316